Test Bank - Massage Therapy-Principles and Practice, 7th Edition (Salvo, 2023), Chapter 1-30 | All Chapters

Test Bank - Massage Therapy-Principles and Practice, 7th
i# i# i# i# i# i# i# i#



Edition (Salvo, 2023), Chapter 1-30 | All Chapters
i# i# i# i# i# i# i# i#

,Test i#Bank i# - i#Pharmacology: i#A i#Patient-Centered i#Nursing i#Process i#Approach i#(9th
i#Edition, i#2017)

PHARMACOLOGY i#9TH i#EDITION i#MCCUISTION i#TEST i#BANK


Tableof Contents i#

Table#iof#i Contents Chapter#i28:#iPeptides,#iAntimalarial,#i and

Chapter#i01:#iDrug#iDevelopment#iand#iEth Anthelmintic
i#ical#
i Considerations Chapter#i29:#iHIV- and#iAIDS-
k


Chapter#i02:#iPharmacokinetics, i#Pharm i#Related# i Drugs

i#acodynamics, i#and Chapter#i30:#iTransplant#iDrugs
i#Pharmacogenetics i#Chapter# i03: i#Chapter # i 31: # i Vaccines # i Chapter

iCultural#
# iConsiderations i#Ch i#apter# i 04: i#32:# iAnticancer# iDrugs

i Complementary#
# i and# i Alternati i#ve Chapter#i33:#iTargeted#iTherapies#ito#iTreat Can k


i Therapies
# i#cer

Chapter i#05: i#Pediatric Chapter#i34:#iBiologic#iResponse i#Modifiers
i#Considerations i#Chapter i#06: i#Chapter# i 35:# i Upper# i Respiratory i#Disorde

i#Geriatric Considerations
k i#Chapter i#rs

i#07: i#Drugs i#in i#Substance i#Use Chapter#i36:#iLower#iRespiratory i#Disorde
i#Disorder i#rs

Chapter i#08: i#The i#Nursing i#Process Chapter i#37: i#Cardiac i#Glycosides,
i#and i#Patient-Centered# i Care i#Antia i#nginals, i#and i#Antidysrhythmics

Chapter i#09: i#Safety i#and i#Quality i # Chapter i#38:# i Diuretics

i#Chapte i#r i#10: i#Drug i#Administration Chapter#i39:#iAntihypertensive
i#Chapter i#11: i#D i#rug i#Calculations Chapter i#40: i#Anticoagulants,

i#Chapter i#12: i#Fluid i#Volu i#me i#and i#Antiplatelet i#s, i#and i#Thrombolytics

i#Electrolytes i#Chapter i#41: i#Antihy i#perlipidemics i#and

Chapter i#13: i#Vitamin i#and i#Mineral i#Peripheral i#Vasodilator i#s

i#Repla i#cement Chapter i#42: i#Gastrointestinal

Chapter i#14: i#Nutritional i#Tract Diso i#rders
k


i#Support Chaptek i#r i#15: i#Adrenergic Chapter i#43: i#Antiulcer i#Drugs
i#Agonists i#and i # Antagoni i#sts i#Chapter i#44: i#Eye i#and i#Ear

Chapter#i16:#iCholinergic Agonists#iand k i#Disorders i#Chapter i#4 i#5:

i#Antagonists i#Dermatologic i#Disorders i#Chapter i#4

Chapter#i17:#iStimulants i#6: i#Pituitary, i#Thyroid, i#Parathyroid,

Chapter#i18:#iDepressants#iChapte i#an i#d i#Adrenal i#Disorders Chapter
k


i#r19:# iAntiseizure# iDrugs i#47: i#Anti i#diabetics

Chapter#i20:#iDrugs#ifor#iParkinsonism#iand#iA Chapter#i48:#iUrinary#iDisorders#iChapter
i#lzheimer's# i Disease i#49:# i Pregnancy# iand # i Preterm i#Labor

Chapter #i 21: #i Drugs i#for#i Neuromuscular i#Chapter# i50:# iLabor,# iDelivery,# iand #
i Postp

i#Disorders # i and i#Muscle # i Spasms i#artum

i#Chapte i#r i#22: i#Antipsychotics i#and Chapter i#51: i#Neonatal i#and
i#Anxiolytics i#Newborn i#Chapter i#52:Women's

Chapter#i23:#iAntidepressants#iand#iMood i#St i#Reproductive i#Health

i#abilizers Chapter#i53:#iMen's#iReproductive#iHealth i#Cha
Chapter#i24:#iAntiinflammatories i#pter i#54: i#Sexually i#Transmitted i#Infections

Chapter#i25:#iAnalgesics i#Chapter i#55: i#Adult and i#Pediatric
k


Chapter#i26:#iAntibacterials
Chapter#i27:#iAntituberculars,#iAntifungals,
i#and# i Antivirals

,Test i#Bank i# - i#Pharmacology: i#A i#Patient-Centered i#Nursing i#Process i#Approach i#(9th
i#Edition, i#2017)

PHARMACOLOGY i#9TH i#EDITION i#MCCUISTION i#TEST i#BANK
Emergency#iDrugs

, Test i#Bank i# - i#Pharmacology: i#A i#Patient-Centered i#Nursing i#Process i#Approach i#(9th
i#Edition, i#2017)

PHARMACOLOGY i#9TH i#EDITION i#MCCUISTION i#TEST i#BANK



Chapter01: DrugDevelopmentandEthicalConsiderations
i# i# i# i# i#




MULTIPLE #i CHOICE

1. The#inurse#iis #i preparing #i to administer#i a#ischedule#iII#i injectable drug #i and#iis#idrawing #i up#ihalf i#of #i the
k k


i#contents i#of i#a i#Single-use i#vial. i#Which i#nursing i#action i#is i#correct?

a. Ask #i another #i nurse#ito#iobserve #i and #i cosign #i wasting #i the#iremaining i#drug #i from #i the #i vial.
b. Keep#ithe#iremaining i#amount in #i the #ipatient’s#i drawer #i to give #i at #i the #i next dose.
k k k


c. Record#ithe #iamount unused #i in #i the#i patient’s#imedication #i record.
k


d. Dispose#iof#i the#ivial#i with#i the#iremaining#idrug #i into#ia#ilocked#icollection#ibox.#i A
i#NS: # iA

Schedule#i II#idrugs#i are #i controlled#i substances, #i and#iall#imust#i be#i accounted#ifor.#iWhen #i wasting i#a #i portio
i#n i#of i#a i#drug, i#another i#nurse i#should i#observe i#and i#cosign i#that i#a i#drug i#was i#wasted.

DIF: #i COGNITIVE #i LEVEL: #i Applying #i (Application)
i TO i#P:#
# i NURSING i#PROCESS: i#Nursing

i#Intervention

MSC:#i NCLEX: i#Physiological#i Integrity: i#Pharmacological #i and#i Parenteral#iTherapies

2. A #i patient i#is i#prescribed i#a#i medication #i and #i asks#i the #i nurse i#if i#the#idrug i#is available i#in #i a #igeneric i#for
k


m. i#The i#nurse i#understands i#that i#a #i generic i#medication i#will i#have i#a i#name i#that
a. is#ia #i registered #i trademark.
b. is#ialways#i capitalized.
c. describes#i the#i drugs#i chemical i#structure.
d. is#inon-
i#proprietary. # i ANS:

iD
#

The i#generic i#name i#is the i#official, i#non-
k


proprietary#i name #i for #i a #i drug.#i The #i brand#i name #i is#i the #i trademark #i name#iand#iis#ialways#i capitalized. #i The#ic
i#hemical i#name i#describes i#the i#chemical i#structure i#of i#the i#drug.

DIF:#iCOGNITIVE#iLEVEL: i#Understanding#i (Comprehension) i#T
i#OP: i#NURSING i#PROCESS: i#N/A

MSC:#i NCLEX: i#Physiological#i Integrity: i#Pharmacological #i and#i Parenteral#iTherapies

3. A i#patient i#receives i#a i#prescription i#on i#which i#the i#provider i#has noted i#that i#a i#generic
k


i#medication i#m i#ay i#be i#given.The i#patient i#asks i#the i#nurse what i#this i#means. i#What i#will i#the i#nurse
k


i#tell i#the i#patient i#abou i#t # i generic drugs?
k


a. They#icontain #i the#isame #i inert i#ingredients#i as#i brand-name #i drugs.
b. They#ihave i#chemical#istructures#i that i#are#i identical#i to #i proprietary#i drugs.
c. They#itend #i to#ibe #i less i#expensive i#than i#brand-name #idrugs.
d. They i#undergo i#extensive i#testing i#before i#they i#are
i#marketed. i#A i#NS: # iC

Generic i#drugs i#are i#approved i#by i#the i#FDA i#if i#they i#are i#proved i#to i#be i#bioequivalent i#to i#the i#brand-
i#name# i drug.#i They#itend# i to# i be #
i less#
i expensive #
i because #
i manufacturers #
i of #
i these #
i drugs #
i do#
i not #
i have

i#to i#do i#the extensive i#testing i#required i#of i#brand-
k


name#i drugs#i before #i marketing. #i They#iare #i not#i identical#i to #i brand-
i#name i#drugs i#and i#often i#have i#different i#inert i#ingredients.

DIF:#i COGNITIVE#iLEVEL: #i Applying i#(Application)
TOP:#iNURSING#iPROCESS:#i Nursing#iIntervention:#iPatient#iTeaching #i MSC:
i#NCLEX: i#Management i#of i#Client i#Care




4. The#inurse#ireviews#i information#i about a#i drug i#and#inotes#ithe#i initials USP#i after#ithe#i drugs#iofficial#i na
k k


i#me. i#The i#nurse i#understands i#that i#this i#designation i#indicates i#the i#drug

a. is#ia#i controlled #i substance.